Valuation: Axogen, Inc.

Market Cap 2.27B 1.97B 1.84B 1.69B 3.18B 217B 3.23B 21.64B 8.49B 108B 8.52B 8.34B 362B P/E 2026 *
-92.1x
P/E 2027 * -3,377x
Enterprise Value 2.27B 1.97B 1.84B 1.69B 3.18B 217B 3.23B 21.64B 8.49B 108B 8.52B 8.34B 362B EV / Sales 2026 *
8.12x
EV / Sales 2027 * 6.85x
Free-Float
95.45%
Yield 2026 *
-
Yield 2027 * -
1 day+2.08%
1 week+6.89%
1 month-8.62%
3 months-2.29%
6 months+21.12%
Current year+28.96%
1 week 38.31
Extreme 38.31
46.15
1 month 38.23
Extreme 38.23
46.95
Current year 27.54
Extreme 27.54
46.95
1 year 12.38
Extreme 12.385
46.95
3 years 3.45
Extreme 3.45
46.95
5 years 3.45
Extreme 3.45
46.95
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 2024-08-08
Director of Finance/CFO 42 2025-05-11
Chief Operating Officer 65 2025-01-09
Director TitleAgeSince
Director/Board Member 65 2016-08-31
Director/Board Member 58 2019-05-14
Chairman 70 2024-08-08
Date Insider Type Main position Quantity % Market Cap.
2/26/26 Free

Chief Executive Officer

98,000 0.1955%
2/26/26 Free

Executive/Senior Manager

78,758 0.1571%
2/26/26 Free

Compliance Officer

92,460 0.1845%
Change 5-day change 1-year change 3-year change Capi.($)
+2.08%+6.89%+222.46%+388.54% 2.22B
-0.43%+1.06%+22.80%+4.67% 214B
-0.61%+1.82%-1.11%-23.56% 138B
+0.10%+4.69%-26.56%+8.92% 125B
+1.59%+5.60%-55.46%-9.87% 68.37B
-0.98%+4.16%+8.52%+4.87% 50.05B
-0.91%+5.13%-22.07%-30.22% 47.67B
-0.25%-0.14%+20.52%+13.63% 39.18B
-0.79%+0.70%+30.67%+36.60% 37.34B
-2.75%+12.28%-4.63%-12.79% 31.59B
Average -0.30%+4.17%+19.51%+38.08% 75.34B
Weighted average by Cap. -0.36%+3.05%-0.93%-0.86%

Financials

2026 *2027 *
Net sales 280M 243M 226M 208M 392M 26.68B 398M 2.67B 1.05B 13.28B 1.05B 1.03B 44.55B 331M 288M 268M 246M 465M 31.61B 472M 3.16B 1.24B 15.74B 1.24B 1.22B 52.77B
Net income -24.99M -21.72M -20.22M -18.56M -35.06M -2.39B -35.6M -238M -93.54M -1.19B -93.85M -91.79M -3.98B -1.26M -1.09M -1.02M -934K -1.76M -120M -1.79M -11.99M -4.71M -59.74M -4.72M -4.62M -200M
Net Debt - -
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Date Price Change Volume
26-07-31 US$42.21 +2.08% 1,223,440
26-07-30 US$41.35 -0.05% 1,394,655
26-07-29 US$41.37 +0.53% 2,509,782
26-07-28 US$41.15 +0.02% 1,365,319
26-07-27 US$41.14 +4.18% 971,235
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
42.21USD
Average target price
53.22USD
Spread / Average Target
+26.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXGN Stock